ERES East Resources Acquisition Company

eResearchTechnology and Pharma Bio-Research Sign Agreement to Deliver Integrated Cardiac Safety and Clinical Pharmacology Services Sixth Clinical Research Organization Enters into Digital Cardiac Safety Monitoring Services Agreement with eResearchTechnology PHILADELPHIA, May 14 /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT), , a leading provider of centralized electrocardiographic (ECG) collection and interpretation services, today announced it has entered into an agreement with Pharma Bio-Research Group B.V. (PBR), a leading provider of Phase I/IIA clinical trials and support services to the pharmaceutical and biotechnology industries. This alliance, the sixth for eRT and second in Europe, enables testing of new drug candidates in conjunction with emerging international cardiac safety regulatory guidance and technical standards. Under the agreement, Pharma Bio-Research will conduct clinical trials at its Phase I unit in Zuidlaren, The Netherlands, while eRT will perform digital collection, measurement, interpretation, review and distribution of cardiac safety data through its EXPeRT workflow-enabled data handling technology. The eRT technology is the first solution designed explicitly to meet emerging international guidance and standards related to cardiac safety monitoring services. "Pharma Bio-Research has extensive clinical research experience since 1984, including the conduct of more complex Phase I studies," said Robert Brown, senior vice president of outsourcing partnerships for eRT. "Our alliance presents a great opportunity for eRT to expand its Thorough Phase I ECG Study partnership program within Europe and will help to meet increasing demand from international drug development organizations for the ability to conduct Thorough Phase I ECG studies in Europe. We are pleased to be announcing the Pharma Bio-Research agreement and look forward to working closely with the Pharma Bio-Research team to ensure effective execution of Thorough Phase I ECG studies." "eRT is the world leading provider of digital ECG collection, processing and interpretation," said Willem Jan Drijfhout, Ph.D., Chief Scientific Officer of PBR. "As the European leader of complex phase I/IIA trials, the partnership between PBR and eRT represents for us another opportunity to serve our clients even better in their need for Thorough Phase I ECG studies, especially since regulations are now demanding such studies to be conducted on a large scale. We look forward to intensifying our relationship with eRT under the current agreement and are convinced that the professional staff of eRT fits well with the high quality culture of PBR." Based in Philadelphia, Pa., eResearchTechnology, Inc. (http://www.ert.com/) is a provider of technology and services to the pharmaceutical, biotechnology and medical device industries on a global basis. The company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG) technology and services to evaluate cardiac safety in clinical development. The company is also a leader in providing technology and services to streamline the clinical trials process by enabling its customers to automate the collection, analysis and distribution of clinical data in all phases of clinical development. Based in Zuidlaren, The Netherlands, Pharma Bio-Research Group B.V. is a full service CRO with 140 total beds and offers the full range of services for phase I/IIA clinical research, bioanalysis, biometrics and report writing with the most competitive time lines, excellent quality, reliability and efficiency. Since 1984, PBR has carried out more than 1,000 clinical studies and more than 2,000 bioanalytical studies. Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand and the company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the company's financial results can be found in the company's reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. DATASOURCE: eResearchTechnology, Inc. CONTACT: Joan Sterlacci, eResearchTechnology, +1-908-203-6473; or Matt Hayden, Hayden Communications, +1-858-456-4533, for eResearchTechnology Web site: http://www.ert.com/

Copyright